3173 results for «270»
3173 results
TAVI: Late-Breaking Trials and Innovations
27 Nov 2022 – From PCR London Valves 2022
Consult this session to discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions, and learn more about the early safety and performance of the Vienna TAVI system, the new-generation transcatheter aortic valve platforms performance in native pure aortic regurgitation, and more!
Rapid-fire abstracts: session 4
27 Nov 2022 – From PCR London Valves 2022
In this PCR LV 2022 session dedicated to TAVI, take advantage of the 7 abstracts to learn more about the impact of TAVI for pure regurgitation on the severity of concomitant mitral regurgitation, the deformation of transcatheter heart valve and haemodynamics after aortic ViV, and much...
Ensuring optimal TAVI outcomes - LIVE case
27 Nov 2022 – From PCR London Valves 2022
A 75-year-old female with diabetes and history of ischemic stroke 5 years ago presents a symptomatic severe aortic valve stenosis in a small annulus.
After pre-dilatation (18 mm balloon), the operators implant an Acurate neo2 23 mm with a sentinel cerebral embolic protection device. Watch them perform...
Hot TAVI topics - Emerging indications
27 Nov 2022 – From PCR London Valves 2022
Consult this session on hot TAVI topics to learn more about the under-treatment problem of patients with aortic valve disease, the rationale behind emerging TAVI indications and ongoing trials, as well as the nuances of patient selection and the key role of cardiac imaging in identifying markers of...
Primary mitral regurgitation: treatment options when the anatomy is complex
27 Nov 2022 – From PCR London Valves 2022
Take a look at these presentations to learn more about complex primary mitral regurgitation (and how to differentiate it from simple disease), to understand why it is complex and to know what the treatment options are.
Repair vs. replacement for the treatment of tricuspid valve disease
27 Nov 2022 – From PCR London Valves 2022
Watch this session on tricuspid valve disease to learn more about its current modes of treatment (including new and emerging devices), to understand which patients are the best candidates for this procedure and to explore the challenges that may be encountered during it.
TAVI: emerging evidence
27 Nov 2022 – From PCR London Valves 2022
Through the 5 abstracts of this PCR LV 2022 session, follow the comparison between last-generation balloon and self-expandable TAVR for bicuspid aortic valve stenosis, and the comparison between multiple tools to assess the risk of mortality after TAVR, evaluate the impact of post-TAVI vascular complications, and...
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
A large-scale, randomized trial of orbital atherectomy vs. conventional balloon angioplasty in severely calcified coronary arteries prior to DES implantation (ECLIPSE)
30 Oct 2024
Nicola Ryan provides her take on the ECLIPSE trial presented by Ajay J. Kirtane at TCT 2024 in Washington.
Author
MERIL announces successful primary outcomes of next-gen Myval THV series in major RCT, presented at EuroPCR 2024 - Earns prestigious late Breaking trial status & The LANCET acceptance.
15 May 2024
Randomised comparison of intravascular lithotripsy vs. cutting balloon treatment in calcified coronary artery disease – The Short-CUT trial
27 Oct 2025
Aaysha Cader provides her take on the Short-CUT trial presented by Suzanne J. Baron at TCT 2025, in San Francisco.
Author
Pursue Classics·Originality - Gusta® Balloon Seminar Salon：Beijing Station
22 Apr 2022
Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial
09 Apr 2024
Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)
Author
Author
